How Prenatal Antidepressant Continuation Protects Mothers

Postpartum depression affects approximately one in seven mothers globally and creates substantial clinical challenges. Therefore, evaluating prenatal antidepressant continuation represents a vital clinical strategy for protecting maternal mental health. Doctors frequently weigh the benefits of ongoing pharmacotherapy against potential risks during pregnancy. However, discontinuing treatment can trigger depressive relapse and heighten postpartum risks. A recent large-scale retrospective cohort study provides essential data regarding medication continuation during gestation.

Clinical Impact of Prenatal Antidepressant Continuation

Researchers analyzed health records from 6,552 patients with a history of depression before pregnancy. Specifically, they evaluated three distinct groups: patients continuing medication, patients stopping then restarting, and patients completely stopping antidepressants. Consequently, the study tracked postpartum depression outcomes up to one year following delivery. Overall, 37.7% of the cohort developed postpartum depression. Furthermore, stopping or restarting antidepressants during pregnancy increased postpartum depression risk compared to continuous therapy. Specifically, complete discontinuation increased the relative risk of severe postpartum depression by 33%. Additionally, pre-pregnancy symptom severity markedly amplified this outcome.

Racial Equity and Shared Clinical Decision-Making

Importantly, the research revealed consistent risk patterns across diverse patient populations. Moreover, statistical analyses showed no significant interactions by race, ethnicity, or patient age. Thus, the clinical benefits of continuing treatment apply broadly to diverse demographics. In addition, patients exhibiting mild depressive symptoms at early screening faced an elevated risk profile. Highest risks occurred among symptomatic patients who discontinued their antidepressant regimen. Therefore, clinicians must conduct thorough symptom screenings early in pregnancy. Ultimately, these findings emphasize personalized shared decision-making between prescribers and expectant mothers.

Frequently Asked Questions

Q1: Does stopping antidepressants during pregnancy increase postpartum depression risk?

Yes. Discontinuing antidepressant medication during pregnancy increases the risk of developing moderate to severe postpartum depression by at least 14% to 33% compared to continuing medication.

Q2: Do race or ethnicity alter the effectiveness of antidepressant continuation?

No. The study demonstrated that the protective benefits of prenatal antidepressant continuation do not vary significantly by race, ethnicity, or patient age.

Q3: How should prescribers manage antidepressant therapy in pregnant patients?

Prescribers should perform early screening for depressive symptoms and engage in shared decision-making, balancing symptom severity and medication history to optimize maternal outcomes.

References

1. Ridout KK et al. Antidepressant Continuation in Pregnancy and Postpartum Depression Risk Across Racial and Ethnic Groups. Am J Obstet Gynecol. 2026 Jul 31. doi: undefined. PMID: 42537893.
2. Bayrampour H et al. The Risk of Relapse of Depression During Pregnancy After Discontinuation of Antidepressants: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2020;81(4):19r13134.
3. Lupattelli A et al. Antidepressant continuation and adherence in pregnancy, and risk of antenatal hospitalization for unipolar major depressive and/or anxiety disorders. J Affect Disord. 2023;339:792-800.